Entheon Biomedical Corp. (ENBI.CN)
CAD 0.17
(0.0%)
CAD 0.17
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 564.31 Thousand CAD | -85.11% |
| 2022 | 3.79 Million CAD | -58.42% |
| 2021 | 9.11 Million CAD | 108.28% |
| 2020 | 4.37 Million CAD | 555.9% |
| 2019 | 667.26 Thousand CAD | 292.47% |
| 2018 | 170.01 Thousand CAD | 44.37% |
| 2017 | 117.76 Thousand CAD | 4612.61% |
| 2016 | 2499.00 CAD | -72.17% |
| 2015 | 8980.00 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 102.06 Thousand CAD | 30.98% |
| 2024 Q1 | 77.92 Thousand CAD | 4.11% |
| 2024 Q3 | 67.27 Thousand CAD | -34.09% |
| 2023 Q4 | 74.85 Thousand CAD | -22.4% |
| 2023 FY | 563.13 Thousand CAD | -85.14% |
| 2023 Q1 | 229.4 Thousand CAD | 144.18% |
| 2023 Q3 | 96.45 Thousand CAD | -40.04% |
| 2023 Q2 | 160.87 Thousand CAD | -29.87% |
| 2022 Q4 | -519.29 Thousand CAD | -154.42% |
| 2022 FY | 3.79 Million CAD | -58.42% |
| 2022 Q3 | 954.26 Thousand CAD | -36.57% |
| 2022 Q2 | 1.5 Million CAD | -18.7% |
| 2022 Q1 | 1.85 Million CAD | -12.23% |
| 2021 Q1 | 3.16 Million CAD | -2.55% |
| 2021 Q2 | 2.09 Million CAD | -33.88% |
| 2021 Q3 | 1.74 Million CAD | -16.62% |
| 2021 Q4 | 2.1 Million CAD | 20.77% |
| 2021 FY | 9.11 Million CAD | 108.28% |
| 2020 Q2 | 44.56 Thousand CAD | 24.8% |
| 2020 FY | 4.37 Million CAD | 555.9% |
| 2020 Q4 | 3.24 Million CAD | 2891.81% |
| 2020 Q3 | 108.61 Thousand CAD | 143.71% |
| 2020 Q1 | 35.71 Thousand CAD | -27.71% |
| 2019 Q4 | 49.39 Thousand CAD | 205.33% |
| 2019 Q3 | 16.17 Thousand CAD | -62.58% |
| 2019 Q2 | 43.22 Thousand CAD | 1.01% |
| 2019 FY | 667.26 Thousand CAD | 292.47% |
| 2019 Q1 | 42.79 Thousand CAD | -22.75% |
| 2018 Q1 | 39.98 Thousand CAD | -41.96% |
| 2018 FY | 170.01 Thousand CAD | 44.37% |
| 2018 Q4 | 55.39 Thousand CAD | 61.62% |
| 2018 Q3 | 34.27 Thousand CAD | -8.73% |
| 2018 Q2 | 37.55 Thousand CAD | -6.08% |
| 2017 Q2 | 3614.00 CAD | 0.0% |
| 2017 Q3 | 35.46 Thousand CAD | 881.21% |
| 2017 Q4 | 68.89 Thousand CAD | 94.27% |
| 2017 FY | 117.76 Thousand CAD | 4612.61% |
| 2016 FY | 2499.00 CAD | -72.17% |
| 2015 FY | 8980.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 5.19 Million CAD | 89.13% |
| Asep Medical Holdings Inc | 7.74 Million CAD | 92.711% |
| BetterLife Pharma Inc. | 3.24 Million CAD | 82.584% |
| BioVaxys Technology Corp. | 2.4 Million CAD | 76.512% |
| ChitogenX Inc. | 2.83 Million CAD | 80.06% |
| Rapid Dose Therapeutics Corp. | 4.2 Million CAD | 86.591% |
| Defence Therapeutics Inc. | 12.65 Million CAD | 95.541% |
| Gemina Laboratories Ltd. | 5.08 Million CAD | 88.904% |
| Glow Lifetech Corp. | 25.71 Thousand CAD | -2094.497% |
| Lexston Life Sciences Corp. | 674.71 Thousand CAD | 16.363% |
| Pharmala Biotech Holdings Inc. | 1.21 Million CAD | 53.633% |
| Doseology Sciences Inc. | 72.08 Thousand CAD | -682.825% |
| MYND Life Sciences Inc. | 1.47 Million CAD | 61.736% |
| Nova Mentis Life Science Corp. | 1.2 Million CAD | 53.064% |
| PharmaTher Holdings Ltd. | 3.04 Million CAD | 81.462% |
| PreveCeutical Medical Inc. | 963.12 Thousand CAD | 41.408% |
| Telescope Innovations Corp. | 6.35 Million CAD | 91.116% |